Gilead Sciences, Inc. (NASDAQ:GILD) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) have earned an average rating of “Moderate Buy” from the twenty-seven research firms that are presently covering the company, Marketbeat.com reports. Eleven equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have given a strong buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $98.39.

A number of brokerages recently issued reports on GILD. Mizuho boosted their price target on Gilead Sciences from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Thursday, November 21st. Cantor Fitzgerald reiterated a “neutral” rating and set a $80.00 price objective on shares of Gilead Sciences in a research note on Wednesday, December 11th. Morgan Stanley upgraded Gilead Sciences from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $87.00 to $113.00 in a research note on Friday, January 10th. Bank of America reaffirmed a “buy” rating and issued a $109.00 price target on shares of Gilead Sciences in a report on Tuesday, December 10th. Finally, Robert W. Baird lifted their target price on Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a report on Thursday, November 7th.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the sale, the chief financial officer now owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. This represents a 1.89 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the sale, the director now directly owns 8,920 shares in the company, valued at approximately $815,198.80. The trade was a 43.21 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 456,234 shares of company stock valued at $42,130,461. Corporate insiders own 0.16% of the company’s stock.

Hedge Funds Weigh In On Gilead Sciences

Hedge funds have recently bought and sold shares of the company. HHM Wealth Advisors LLC boosted its holdings in Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 154 shares during the period. nVerses Capital LLC purchased a new position in Gilead Sciences in the third quarter valued at approximately $25,000. YANKCOM Partnership acquired a new stake in Gilead Sciences during the 4th quarter worth $28,000. Decker Retirement Planning Inc. acquired a new stake in shares of Gilead Sciences during the fourth quarter worth about $29,000. Finally, Valued Wealth Advisors LLC lifted its stake in Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 161 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $97.20 on Monday. The stock’s fifty day moving average is $92.42 and its 200 day moving average is $85.87. The firm has a market capitalization of $121.14 billion, a PE ratio of 1,080.00, a PEG ratio of 1.34 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. Gilead Sciences has a fifty-two week low of $62.07 and a fifty-two week high of $98.90.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. The firm had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Gilead Sciences’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same period last year, the company earned $2.29 EPS. On average, sell-side analysts anticipate that Gilead Sciences will post 4.36 earnings per share for the current year.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.